{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:56:32Z","timestamp":1789160192004,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2024JJ5599"],"award-info":[{"award-number":["2024JJ5599"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06647-4","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T09:02:48Z","timestamp":1751360568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["METTL3 regulates Ambra1 expression in an m6A-YTHDF2-dependent manner to promote mantle cell lymphoma progression"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2483-2122","authenticated-orcid":false,"given":"Shujun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjia","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianjing","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"6647_CR1","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/ajh.25487","volume":"94","author":"P Jain","year":"2019","unstructured":"Jain P, Wang M. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. Am J Hematol. 2019;94:710\u201325.","journal-title":"Am J Hematol"},{"key":"6647_CR2","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/ajh.26523","volume":"97","author":"P Jain","year":"2022","unstructured":"Jain P, Wang ML. Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol. 2022;97:638\u201356.","journal-title":"Am J Hematol"},{"key":"6647_CR3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/bjh.18697","volume":"201","author":"MR Wilson","year":"2023","unstructured":"Wilson MR, Barrett A, Cheah CY, Eyre TA. How I manage mantle cell lymphoma: indolent versus aggressive disease. Br J Haematol. 2023;201:185\u201398.","journal-title":"Br J Haematol"},{"key":"6647_CR4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40164-019-0126-0","volume":"8","author":"A Ladha","year":"2019","unstructured":"Ladha A, Zhao J, Epner EM, Pu JJ. Mantle cell lymphoma and its management: where are we now? Exp Hematol Oncol. 2019;8:2.","journal-title":"Exp Hematol Oncol"},{"key":"6647_CR5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/bjh.15283","volume":"182","author":"P McKay","year":"2018","unstructured":"McKay P, Leach M, Jackson B, Robinson S, Rule S. Guideline for the management of mantle cell lymphoma. Br J Haematol. 2018;182:46\u201362.","journal-title":"Br J Haematol"},{"key":"6647_CR6","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1007\/s10495-022-01762-9","volume":"27","author":"YQ Qin","year":"2022","unstructured":"Qin YQ, Liu SY, Lv ML, Sun WL. Ambra1 in cancer: implications for clinical oncology. Apoptosis. 2022;27:720\u20139.","journal-title":"Apoptosis"},{"key":"6647_CR7","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1038\/s41467-021-22772-2","volume":"12","author":"L Di Leo","year":"2021","unstructured":"Di Leo L, Bodemeyer V, Bosisio FM, Claps G, Carretta M, Rizza S, Faienza F, Frias A, Khan S, Bordi M, et al. Loss of Ambra1 promotes melanoma growth and invasion. Nat Commun. 2021;12:2550.","journal-title":"Nat Commun"},{"key":"6647_CR8","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/s41586-021-03445-y","volume":"592","author":"D Simoneschi","year":"2021","unstructured":"Simoneschi D, Rona G, Zhou N, Jeong YT, Jiang S, Milletti G, Arbini AA, O\u2019Sullivan A, Wang AA, Nithikasem S, et al. CRL4(AMBRA1) is a master regulator of D-type cyclins. Nature. 2021;592:789\u201393.","journal-title":"Nature"},{"key":"6647_CR9","doi-asserted-by":"publisher","first-page":"8389","DOI":"10.1038\/s41598-023-35096-6","volume":"13","author":"Z Jiang","year":"2023","unstructured":"Jiang Z, Zhang A, Wei W, Li S. Ambra1 modulates the sensitivity of mantle cell lymphoma to Palbociclib by regulating Cyclin D1. Sci Rep. 2023;13:8389.","journal-title":"Sci Rep"},{"key":"6647_CR10","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/j.cell.2012.05.003","volume":"149","author":"KD Meyer","year":"2012","unstructured":"Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE, Jaffrey SR. Comprehensive analysis of mRNA methylation reveals enrichment in 3\u2019 UTRs and near stop codons. Cell. 2012;149:1635\u201346.","journal-title":"Cell"},{"key":"6647_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nature12730","volume":"505","author":"X Wang","year":"2014","unstructured":"Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han D, Fu Y, Parisien M, Dai Q, Jia G, et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature. 2014;505:117\u201320.","journal-title":"Nature"},{"key":"6647_CR12","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12943-019-1109-9","volume":"18","author":"L He","year":"2019","unstructured":"He L, Li H, Wu A, Peng Y, Shu G, Yin G. Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 2019;18:176.","journal-title":"Mol Cancer"},{"key":"6647_CR13","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41422-018-0034-6","volume":"28","author":"X Deng","year":"2018","unstructured":"Deng X, Su R, Weng H, Huang H, Li Z, Chen J. RNA N(6)-methyladenosine modification in cancers: current status and perspectives. Cell Res. 2018;28:507\u201317.","journal-title":"Cell Res"},{"key":"6647_CR14","first-page":"3682","volume":"18","author":"W Zhang","year":"2019","unstructured":"Zhang W, He X, Hu J, Yang P, Liu C, Wang J, An R, Zhen J, Pang M, Hu K, et al. Dysregulation of N(6)-methyladenosine regulators predicts poor patient survival in mantle cell lymphoma. Oncol Lett. 2019;18:3682\u201390.","journal-title":"Oncol Lett"},{"key":"6647_CR15","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1182\/blood.2019003764","volume":"137","author":"H Han","year":"2021","unstructured":"Han H, Fan G, Song S, Jiang Y, Qian C, Zhang W, Su Q, Xue X, Zhuang W, Li B. piRNA-30473 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in DLBCL. Blood. 2021;137:1603\u201314.","journal-title":"Blood"},{"key":"6647_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s11658-023-00445-w","volume":"28","author":"X Chen","year":"2023","unstructured":"Chen X, Lu T, Cai Y, Han Y, Ding M, Chu Y, Zhou X, Wang X. KIAA1429-mediated m6A modification of CHST11 promotes progression of diffuse large B-cell lymphoma by regulating Hippo-YAP pathway. Cell Mol Biol Lett. 2023;28:32.","journal-title":"Cell Mol Biol Lett"},{"key":"6647_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jare.2023.10.010","volume":"63","author":"X Chen","year":"2024","unstructured":"Chen X, Lu T, Ding M, Cai Y, Yu Z, Zhou X, Wang X. Targeting YTHDF2 inhibits tumorigenesis of diffuse large B-cell lymphoma through ACER2-mediated ceramide catabolism. J Adv Res. 2024;63:17\u201333.","journal-title":"J Adv Res"},{"key":"6647_CR18","doi-asserted-by":"publisher","first-page":"217058","DOI":"10.1016\/j.canlet.2024.217058","volume":"597","author":"S Wu","year":"2024","unstructured":"Wu S, Wang H, Yang Q, Liu Z, Du J, Wang L, Chen S, Lu Q, Yang DH. METTL3 regulates M6A methylation-modified EBV-pri-miR-BART3-3p to promote NK\/T cell lymphoma growth. Cancer Lett. 2024;597:217058.","journal-title":"Cancer Lett"},{"key":"6647_CR19","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/iub.2410","volume":"73","author":"H Ma","year":"2021","unstructured":"Ma H, Shen L, Yang H, Gong H, Du X, Li J. m6A methyltransferase wilms\u2019 tumor 1-associated protein facilitates cell proliferation and cisplatin resistance in NK\/T cell lymphoma by regulating dual-specificity phosphatases 6 expression via m6A RNA methylation. IUBMB Life. 2021;73:108\u201317.","journal-title":"IUBMB Life"},{"key":"6647_CR20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12943-019-1036-9","volume":"18","author":"J Han","year":"2019","unstructured":"Han J, Wang JZ, Yang X, Yu H, Zhou R, Lu HC, Yuan WB, Lu JC, Zhou ZJ, Lu Q, et al. METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221\/222 maturation in m6A-dependent manner. Mol Cancer. 2019;18:110.","journal-title":"Mol Cancer"},{"key":"6647_CR21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.tig.2019.12.007","volume":"36","author":"Y Lee","year":"2020","unstructured":"Lee Y, Choe J, Park OH, Kim YK. Molecular mechanisms driving mRNA degradation by m(6)A modification. Trends Genet. 2020;36:177\u201388.","journal-title":"Trends Genet"},{"key":"6647_CR22","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1242\/jcs.168153","volume":"128","author":"V Cianfanelli","year":"2015","unstructured":"Cianfanelli V, De Zio D, Di Bartolomeo S, Nazio F, Strappazzon F, Cecconi F. Ambra1 at a glance. J Cell Sci. 2015;128:2003\u20138.","journal-title":"J Cell Sci"},{"key":"6647_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/ncb3072","volume":"17","author":"V Cianfanelli","year":"2015","unstructured":"Cianfanelli V, Fuoco C, Lorente M, Salazar M, Quondamatteo F, Gherardini PF, De Zio D, Nazio F, Antonioli M, D\u2019Orazio M, et al. AMBRA1 links autophagy to cell proliferation and tumorigenesis by promoting c-Myc dephosphorylation and degradation. Nat Cell Biol. 2015;17:20\u201330.","journal-title":"Nat Cell Biol"},{"key":"6647_CR24","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41586-021-03422-5","volume":"592","author":"E Maiani","year":"2021","unstructured":"Maiani E, Milletti G, Nazio F, Holdgaard SG, Bartkova J, Rizza S, Cianfanelli V, Lorente M, Simoneschi D, Di Marco M, et al. AMBRA1 regulates Cyclin D to guard S-phase entry and genomic integrity. Nature. 2021;592:799\u2013803.","journal-title":"Nature"},{"key":"6647_CR25","doi-asserted-by":"crossref","unstructured":"Frias A, Di Leo L, Antoranz A, Nazerai L, Carretta M, Bodemeyer V, Pagliuca C, Dahl C, Claps G, Mandelli GE et al. Ambra1 modulates the tumor immune microenvironment and response to PD-1 Blockade in melanoma. J Immunother Cancer 2023, 11.","DOI":"10.1136\/jitc-2022-006389"},{"key":"6647_CR26","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.1158\/0008-5472.CAN-21-0431","volume":"81","author":"J Liu","year":"2021","unstructured":"Liu J, Yuan B, Cao J, Luo H, Gu S, Zhang M, Ding R, Zhang L, Zhou F, Hung MC, et al. AMBRA1 promotes TGF\u03b2 signaling via nonproteolytic polyubiquitylation of Smad4. Cancer Res. 2021;81:5007\u201320.","journal-title":"Cancer Res"},{"key":"6647_CR27","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s10495-022-01718-z","volume":"27","author":"WL Sun","year":"2022","unstructured":"Sun WL, He LY, Liang L, Liu SY, Luo J, Lv ML, Cai ZW. Ambra1 regulates apoptosis and chemosensitivity in breast cancer cells through the Akt-FoxO1-Bim pathway. Apoptosis. 2022;27:329\u201341.","journal-title":"Apoptosis"},{"key":"6647_CR28","doi-asserted-by":"crossref","unstructured":"Liu J, Chen Z, Guo J, Wang L, Liu X. Ambra1 induces autophagy and desensitizes human prostate cancer cells to cisplatin. Biosci Rep 2019, 39.","DOI":"10.1042\/BSR20170770"},{"key":"6647_CR29","doi-asserted-by":"crossref","unstructured":"Zhang C, Wang K, Tao J, Zheng C, Zhai L. MYC-dependent MiR-7-5p regulated apoptosis and autophagy in diffuse large B cell lymphoma by targeting AMBRA1. Mol Cell Biochem 2024.","DOI":"10.1007\/s11010-024-04946-w"},{"key":"6647_CR30","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.bbrc.2017.08.019","volume":"491","author":"H Akatsuka","year":"2017","unstructured":"Akatsuka H, Kuga S, Masuhara K, Davaadorj O, Okada C, Iida Y, Okada Y, Fukunishi N, Suzuki T, Hosomichi K, et al. AMBRA1 is involved in T cell receptor-mediated metabolic reprogramming through an ATG7-independent pathway. Biochem Biophys Res Commun. 2017;491:1098\u2013104.","journal-title":"Biochem Biophys Res Commun"},{"key":"6647_CR31","doi-asserted-by":"publisher","first-page":"108613","DOI":"10.1016\/j.biopha.2019.108613","volume":"112","author":"T Sun","year":"2019","unstructured":"Sun T, Wu R, Ming L. The role of m6A RNA methylation in cancer. Biomed Pharmacother. 2019;112:108613.","journal-title":"Biomed Pharmacother"},{"key":"6647_CR32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13045-020-00951-w","volume":"13","author":"C Zeng","year":"2020","unstructured":"Zeng C, Huang W, Li Y, Weng H. Roles of METTL3 in cancer: mechanisms and therapeutic targeting. J Hematol Oncol. 2020;13:117.","journal-title":"J Hematol Oncol"},{"key":"6647_CR33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.canlet.2017.11.018","volume":"415","author":"X Cai","year":"2018","unstructured":"Cai X, Wang X, Cao C, Gao Y, Zhang S, Yang Z, Liu Y, Zhang X, Zhang W, Ye L. HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7\u00a0g. Cancer Lett. 2018;415:11\u20139.","journal-title":"Cancer Lett"},{"key":"6647_CR34","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/s41467-021-21514-8","volume":"12","author":"H Yin","year":"2021","unstructured":"Yin H, Zhang X, Yang P, Zhang X, Peng Y, Li D, Yu Y, Wu Y, Wang Y, Zhang J, et al. RNA m6A methylation orchestrates cancer growth and metastasis via macrophage reprogramming. Nat Commun. 2021;12:1394.","journal-title":"Nat Commun"},{"key":"6647_CR35","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/nature24678","volume":"552","author":"I Barbieri","year":"2017","unstructured":"Barbieri I, Tzelepis K, Pandolfini L, Shi J, Mill\u00e1n-Zambrano G, Robson SC, Aspris D, Migliori V, Bannister AJ, Han N, et al. Promoter-bound METTL3 maintains myeloid leukaemia by m(6)A-dependent translation control. Nature. 2017;552:126\u201331.","journal-title":"Nature"},{"key":"6647_CR36","doi-asserted-by":"publisher","first-page":"8606","DOI":"10.1038\/s41598-023-35777-2","volume":"13","author":"S Meng","year":"2023","unstructured":"Meng S, Xia Y, Li M, Wu Y, Wang D, Zhou Y, Ma D, Ye J, Sun T, Ji C. NCBP1 enhanced proliferation of DLBCL cells via METTL3-mediated m6A modification of c-Myc. Sci Rep. 2023;13:8606.","journal-title":"Sci Rep"},{"key":"6647_CR37","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41392-020-00450-x","volume":"6","author":"X Jiang","year":"2021","unstructured":"Jiang X, Liu B, Nie Z, Duan L, Xiong Q, Jin Z, Yang C, Chen Y. The role of m6A modification in the biological functions and diseases. Signal Transduct Target Ther. 2021;6:74.","journal-title":"Signal Transduct Target Ther"},{"key":"6647_CR38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40164-022-00269-y","volume":"11","author":"X Chen","year":"2022","unstructured":"Chen X, Zhou X, Wang X. m(6)A binding protein YTHDF2 in cancer. Exp Hematol Oncol. 2022;11:21.","journal-title":"Exp Hematol Oncol"},{"key":"6647_CR39","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41586-021-03536-w","volume":"593","author":"E Yankova","year":"2021","unstructured":"Yankova E, Blackaby W, Albertella M, Rak J, De Braekeleer E, Tsagkogeorga G, Pilka ES, Aspris D, Leggate D, Hendrick AG, et al. Small-molecule Inhibition of METTL3 as a strategy against myeloid leukaemia. Nature. 2021;593:597\u2013601.","journal-title":"Nature"},{"key":"6647_CR40","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41419-022-04817-6","volume":"13","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Peng X, Zhou Q, Tan L, Zhang C, Lin S, Long M. METTL3-mediated m6A modification of STEAP2 mRNA inhibits papillary thyroid cancer progress by blocking the Hedgehog signaling pathway and epithelial-to-mesenchymal transition. Cell Death Dis. 2022;13:358.","journal-title":"Cell Death Dis"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06647-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06647-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06647-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T09:02:53Z","timestamp":1751360573000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06647-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6647"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06647-4","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"29 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments have been approved by the Ethics Committee for Animal Experimentation of Xiangya Hospital of Central South University (Prot. ID 202203003) and followed with the ARRIVE Guideline.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing interests that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"703"}}